abstract |
Provided herein are methods of treating cancer with a TPH1 inhibitor. In certain embodiments, methods are provided which display remarkable efficacy and bioavailability for the treatment of certain tumors, for example, a neuroendocrine tumor in a human patient. In certain embodiments, the methods comprising treating the patient with telotristat, a telotristat prodrug, or a pharmaceutically acceptable salt thereof, which can be administered either alone or in combination with other anticancer or antidiarrheal agents. |